Cedar Hill Associates’s Viatris VTRS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2018
Q4
$528K Sell
19,289
-8,933
-32% -$289K 0.2% 78
2018
Q3
$1.03M Sell
28,222
-3,520
-11% -$132K 0.23% 68
2018
Q2
$1.15M Sell
31,742
-2,275
-7% -$89.3K 0.24% 72
2018
Q1
$1.4M Sell
34,017
-9,858
-22% -$420K 0.28% 66
2017
Q4
$1.86M Sell
43,875
-3,200
-7% -$122K 0.32% 61
2017
Q3
$1.48M Sell
47,075
-108,995
-70% -$3.7M 0.25% 66
2017
Q2
$6.06M Sell
156,070
-6,680
-4% -$256K 1.26% 40
2017
Q1
$6.35M Buy
+162,750
New +$6.56M 1.32% 40

Other funds holding VTRS

Cedar Hill Associates's VTRS Position: Q4 2018 in Review

Cedar Hill Associates reduced its Viatris (VTRS) stake by 32% in Q4 2018, selling an estimated $289K and leaving 19,289 shares worth $528K. The position accounts for 0.2% of the portfolio, ranked #78.

Cedar Hill Associates first reported a position in VTRS in Q1 2017 and has held it in 8 quarters since. The position peaked at $6.35M in Q1 2017. 502 funds tracked by Wall St. Rank hold VTRS as of Q4 2018.

  • Cedar Hill Associates held 19,289 shares of Viatris worth $528K as of Q4 2018.
  • Cedar Hill Associates sold 8,933 Viatris shares in Q4 2018, an estimated $289K.
  • Viatris made up 0.2% of Cedar Hill Associates's portfolio in Q4 2018, its #78 holding.
  • Cedar Hill Associates first reported a position in Viatris in Q1 2017 and has held it in 8 quarters since.
  • Cedar Hill Associates's Viatris position peaked at $6.35M in Q1 2017.
  • 502 funds tracked by Wall St. Rank held Viatris as of Q4 2018.

Based on Cedar Hill Associates's 13F filing for Q4 2018, filed 13 Feb 2019.